Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Incyte Corporation stock logo
INCY
Incyte
$68.46
+0.4%
$65.52
$53.56
$83.95
$13.25B0.681.97 million shs1.27 million shs
MKS Inc. stock logo
MKSI
MKS
$104.77
+0.1%
$88.32
$54.84
$147.40
$7.07B1.881.05 million shs569,731 shs
Magnachip Semiconductor Corp. stock logo
MX
Magnachip Semiconductor
$4.11
+2.0%
$3.70
$2.51
$5.98
$148.21M0.86239,554 shs47,843 shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$454.64
-0.5%
$450.84
$377.85
$519.88
$116.75B0.411.42 million shs763,957 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Incyte Corporation stock logo
INCY
Incyte
0.00%+0.13%-0.45%+13.55%+19.41%
MKS Inc. stock logo
MKSI
MKS
0.00%+4.55%+18.20%+66.33%-21.85%
Magnachip Semiconductor Corp. stock logo
MX
Magnachip Semiconductor
0.00%+1.73%+11.08%+45.49%-16.46%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.00%+3.02%+0.92%-4.20%-4.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Incyte Corporation stock logo
INCY
Incyte
4.4167 of 5 stars
2.13.00.02.83.22.53.1
MKS Inc. stock logo
MKSI
MKS
4.2469 of 5 stars
2.52.01.72.92.31.72.5
Magnachip Semiconductor Corp. stock logo
MX
Magnachip Semiconductor
2.4472 of 5 stars
3.35.00.00.00.01.70.6
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
4.7669 of 5 stars
3.35.00.03.34.02.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Incyte Corporation stock logo
INCY
Incyte
2.22
Hold$74.538.87% Upside
MKS Inc. stock logo
MKSI
MKS
2.92
Moderate Buy$130.8224.86% Upside
Magnachip Semiconductor Corp. stock logo
MX
Magnachip Semiconductor
2.50
Moderate Buy$6.0045.99% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.54
Moderate Buy$511.6212.53% Upside

Current Analyst Ratings Breakdown

Latest MKSI, VRTX, INCY, and MX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
MKS Inc. stock logo
MKSI
MKS
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$110.00 ➝ $120.00
6/23/2025
Incyte Corporation stock logo
INCY
Incyte
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetSector Perform ➝ Sector Perform$67.00
6/23/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$550.00
6/20/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$464.00 ➝ $460.00
6/17/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetSector Perform ➝ Sector Perform$423.00 ➝ $420.00
6/16/2025
Incyte Corporation stock logo
INCY
Incyte
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$75.00 ➝ $107.00
6/3/2025
Incyte Corporation stock logo
INCY
Incyte
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/3/2025
Incyte Corporation stock logo
INCY
Incyte
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$61.00
5/27/2025
Incyte Corporation stock logo
INCY
Incyte
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$72.00 ➝ $73.00
5/23/2025
MKS Inc. stock logo
MKSI
MKS
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$93.00 ➝ $100.00
5/23/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Incyte Corporation stock logo
INCY
Incyte
$4.24B3.12$0.55 per share123.64$17.90 per share3.82
MKS Inc. stock logo
MKSI
MKS
$3.59B1.97$12.24 per share8.56$34.50 per share3.04
Magnachip Semiconductor Corp. stock logo
MX
Magnachip Semiconductor
$231.74M0.64N/AN/A$7.44 per share0.55
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$11.02B10.59N/AN/A$63.72 per share7.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Incyte Corporation stock logo
INCY
Incyte
$32.62M$0.32213.9410.470.580.48%2.77%1.77%7/29/2025 (Estimated)
MKS Inc. stock logo
MKSI
MKS
$190M$3.3531.2712.171.186.21%20.67%5.49%8/6/2025 (Estimated)
Magnachip Semiconductor Corp. stock logo
MX
Magnachip Semiconductor
-$54.31M-$1.28N/AN/AN/A-21.01%-9.69%-7.07%7/30/2025 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-$535.60M-$3.92N/A25.96N/A-8.91%-3.36%-2.42%7/30/2025 (Estimated)

Latest MKSI, VRTX, INCY, and MX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Magnachip Semiconductor Corp. stock logo
MX
Magnachip Semiconductor
-$0.13N/AN/AN/A$47.20 millionN/A
7/29/2025Q2 2025
Incyte Corporation stock logo
INCY
Incyte
$1.38N/AN/AN/A$1.15 billionN/A
5/7/2025Q1 2025
MKS Inc. stock logo
MKSI
MKS
$1.42$1.71+$0.29$0.77$913.59 million$936.00 million
5/5/2025Q1 2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.29$4.06-$0.23$2.49$2.85 billion$2.77 billion
4/29/2025Q1 2025
Incyte Corporation stock logo
INCY
Incyte
$1.01$1.16+$0.15$0.80$996.17 million$1.05 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Incyte Corporation stock logo
INCY
Incyte
N/AN/AN/AN/AN/A
MKS Inc. stock logo
MKSI
MKS
$0.880.84%N/A26.27%N/A
Magnachip Semiconductor Corp. stock logo
MX
Magnachip Semiconductor
N/AN/AN/AN/AN/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest MKSI, VRTX, INCY, and MX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/12/2025
MKS Inc. stock logo
MKSI
MKS
quarterly$0.220.96%5/27/20255/27/20256/6/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Incyte Corporation stock logo
INCY
Incyte
0.01
2.04
2.00
MKS Inc. stock logo
MKSI
MKS
1.87
3.11
1.96
Magnachip Semiconductor Corp. stock logo
MX
Magnachip Semiconductor
0.10
4.51
3.83
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.01
2.65
2.29

Institutional Ownership

CompanyInstitutional Ownership
Incyte Corporation stock logo
INCY
Incyte
96.97%
MKS Inc. stock logo
MKSI
MKS
99.79%
Magnachip Semiconductor Corp. stock logo
MX
Magnachip Semiconductor
74.26%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
Incyte Corporation stock logo
INCY
Incyte
17.80%
MKS Inc. stock logo
MKSI
MKS
0.51%
Magnachip Semiconductor Corp. stock logo
MX
Magnachip Semiconductor
5.70%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Incyte Corporation stock logo
INCY
Incyte
2,617193.57 million159.12 millionOptionable
MKS Inc. stock logo
MKSI
MKS
10,20067.45 million67.10 millionOptionable
Magnachip Semiconductor Corp. stock logo
MX
Magnachip Semiconductor
90036.06 million34.01 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,100256.80 million256.28 millionOptionable

Recent News About These Companies

The Best Stocks to Invest $1,000 In Right Now

New MarketBeat Followers Over Time

Media Sentiment Over Time

Incyte stock logo

Incyte NASDAQ:INCY

$68.46 +0.29 (+0.43%)
Closing price 07/3/2025 03:25 PM Eastern
Extended Trading
$67.23 -1.23 (-1.80%)
As of 07/3/2025 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

MKS stock logo

MKS NASDAQ:MKSI

$104.77 +0.15 (+0.14%)
Closing price 07/3/2025 03:35 PM Eastern
Extended Trading
$106.00 +1.23 (+1.17%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MKS Instruments, Inc. provides foundational technology solutions to semiconductor manufacturing, electronics and packaging, and specialty industrial applications in the United States, Germany, China, South Korea, and internationally. It operates through Vacuum Solutions Division (VSD), Photonics Solutions Division (PSD), and Material Solutions Division (MSD) segments. The VSD segment provides foundational technology solutions, including pressure measurement and control, flow measurement and control, gas and vapor delivery, gas composition analysis, electronic control technology, reactive gas generation and delivery, power generation and delivery, and vacuum technology. The PSD segment offers range of solutions, which include lasers, beam measurement and profiling, precision motion control, vibration isolation systems, photonics instruments, temperature sensing, opto-mechanical components, optical elements, systems for flexible PCB laser processing, and laser-based systems, as well as high density interconnect PCB and package manufacturing. The MSD segment develops, process, and manufactures technologies comprising advanced surface modification, electroless and electrolytic plating, and surface finishing for chemistry, equipment, software, and services markets, as well as high-technology applications. In addition, the company sells its products and services through direct sales, network of independent distributors, and sales representatives, as well as websites, including product catalogs. The company was incorporated in 1961 and is headquartered in Andover, Massachusetts.

Magnachip Semiconductor stock logo

Magnachip Semiconductor NYSE:MX

$4.11 +0.08 (+1.99%)
Closing price 07/3/2025 03:35 PM Eastern
Extended Trading
$4.10 -0.01 (-0.24%)
As of 04:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Magnachip Semiconductor Corporation, together with its subsidiaries, designs, manufactures, and supplies analog and mixed-signal semiconductor platform solutions for communications, the Internet of Things, consumer, computing, industrial, and automotive applications. It provides display solutions, including source and gate drivers, and timing controllers that cover a range of flat panel displays used in mobile communications, automotive, entertainment devices, monitors, notebook PCs, tablet PC and TVs applied with liquid crystal display, organic light emitting diodes (OLED), and micro light emitting diode (Micro LED) panel. The company also offers metal oxide semiconductor field-effect transistors, insulated-gate bipolar transistors, AC-DC converters, DC-DC converters, LED drivers, regulators, and power management integrated circuits for a range of devices comprising televisions, smartphones, mobile phones, wearable devices, desktop PCs, notebooks, tablet PCs, and other consumer electronics, as well as for power suppliers, e-bikes, photovoltaic inverters, LED lighting, and motor drives; and OLED display driver integrated circuit products. It serves consumer, computing, communication, automotive and industrial electronics OEMs, original design manufacturers, and electronics manufacturing services companies, as well as subsystem designers in the Asia Pacific, the United States, and Europe. The company sells its products through a direct sales force, as well as through a network of agents and distributors. Magnachip Semiconductor Corporation was incorporated in 2003 and is based in Cheongju-si, South Korea.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$454.64 -2.40 (-0.52%)
Closing price 07/3/2025 03:51 PM Eastern
Extended Trading
$458.16 +3.53 (+0.78%)
As of 04:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.